Rationally Speaking Podcast New York City Skeptics

The idea of giving poor people cash, no strings attached, is "very unappealing" for most donors, admits economist Michael Faye -- but it's still one of the best ways to help the poor. Michael and Julia discuss the philosophy behind his organization (GiveDirectly), the evidence we have so far about cash transfers as an anti-poverty intervention, and the various concerns people have about it: How long-lasting are the effects? Does it make recipients less likely to work? Does it cause inflation?

Humanity could thrive for millions of years -- unless our future is cut short by an existential catastrophe. Oxford philosopher Toby Ord explains the possible existential risks we face, including climate change, pandemics, and artificial intelligence. Toby and Julia discuss what led him to take existential risk more seriously, which risks he considers underrated vs. overrated, and how to estimate the probability of existential risk.

Kevin Esvelt, a scientist at MIT, argues that research intended to prevent pandemics is actually putting us in a lot more danger. Also discussed: Kevin's own research on engineering wild animal species. Are the risks worth the benefits?

Ezra Klein explains how Republican and Democrats in the US became so different from each other, ideologically and demographically, and why that trend + our institutions =  political gridlock. Questions covered include: Is polarization necessarily bad? Has the left polarized more than the right? And what should we make of polls that seem to show Republicans and Democrats used to agree on immigration policy?

Kathryn Paige Harden, author of “The Genetic Lottery: Why DNA Matters for Social Equality” explains what scientists have learned about how our genes affect our educational success. Why is this research so controversial? And is it worth doing anyway?

Journalist Kelsey Piper (Future Perfect / Vox) discusses lessons learned from covering COVID: What has she been wrong about, and why? How much can we trust the CDC's advice? What does the evidence look like for different drugs like Fluvoxamine and Ivermectin? And should regular people really try to evaluate the evidence themselves instead of deferring to experts?